Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Arix Bioscience PLC (ARIX)
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

05-Apr-2022 / 16:28 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS...
Quelle: Börse Online RSS Feed